192575-19-2
中文名稱
PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID;
英文名稱
PPADS TETRASODIUM SALT
CAS
192575-19-2
分子式
C14H10N3Na4O12PS2
分子量
599.3
MOL 文件
192575-19-2.mol
192575-19-2 結(jié)構(gòu)式
基本信息
中文別名
化合物 T16564 英文別名
PPADSPPADS Tetrasodium
4'-disulfonic acid
PPADS (sodium salt)
PPADS TETRASODIUM SALT
PPADS tetrasodium salt hydrate
PPADS tetrasodium salt, anhydrous
Pyridoxalphosphate-6-azophenyl-2'
pyridoxal-phosphate-6-azophenyl-2',4'- disulfoni
PYRIDOXALPHOSPHATE-6-AZOPHENYL-2',4'-DISULPHONIC ACID 4NA
物理化學(xué)性質(zhì)
儲(chǔ)存條件−20°C
儲(chǔ)存條件−20°C
溶解度H2O: >10 mg/mL
溶解度H2O: >10 mg/mL
形態(tài)solid
顏色red to orange
水溶解性溶于水至100mM
穩(wěn)定性在水溶液中不穩(wěn)定
PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID;價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-101044 | PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID; PPADS tetrasodium | 192575-19-2 | 1mg | 370元 |
| 2024/11/08 | HY-101044 | PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID; PPADS tetrasodium | 192575-19-2 | 5mg | 750元 |
| 2024/11/08 | HY-101044 | PYRIDOXALPHOSPHATE-6-AZOPHENYL-2';4'-DISULFONIC ACID; PPADS tetrasodium | 192575-19-2 | 10 mM * 1 mLin Water | 989元 |
常見問(wèn)題列表
生物活性
PPADS tetrasodiuma 是一種非選擇性 P2X 受體拮抗劑。PPADS tetrasodiuma 阻斷重組P2X1、-2、-3、-5，IC50 范圍為1～2.6 μM。PPADS-tetrasodiuma 阻斷天然 P2Y2 樣 (IC50~0.9 mM) 和重組 P2Y4 (IC50~15 mM) 受體。PPADS tetrasodiuma 是豚鼠氣道平滑肌 Na/Ca2? 交換逆模式的抑制劑。體外研究
PPADS tetrasodiuma (1-30 μM; 10-50 minutes) inhibits Na+/Ca2+ exchanger reverse mode (NCXREV) in a time- and concentration dependent manner.
PPADS tetrasodiuma is effective at other native and recombinant P2XRs. At human P2XRs sensitivity to PPADS tetrasodiuma depended on the subtype and was highest at the hP2X1, -2, -3, -5, and -7Rs with an IC50 of ～1–3 and ～30 μM for the hP2X4R.
體內(nèi)研究
PPADS tetrasodiuma (15-60 mg/100g body weight (BW); i.p.; every 12 hours for 8 days) inhibits glomerular mesangial cells (MC) proliferation without altering proliferation of non-MC in vivo in mesangial proliferative glomerulonephritis.
| Animal Model: | Male Sprague-Dawley ratsweighing 160 to 200 g (anti-Thy1 disease mode) |
| Dosage: | 15 mg/100g BW, 30 mg/100g BW, 60 mg/100g BW |
| Administration: | i.p.; every 12 hours for 8 days (the first PPADS injection was administered 60 minutes after disease induction, and the loading dose always contained double the amount of PPADS compared to the following injections.) |
| Result: | Specifically and dose-dependently reduced early (day 3) glomerular mesangial cell proliferation without altering proliferation of non-MC. |